Document Detail


Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma.
MedLine Citation:
PMID:  20571355     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Imexon [AOP99.0001 (4-imino-1,3-diazobicyclo[3. 1. 0]-hexan-2-one)] belongs to a novel class of promising anticancer agents that induce tumor apoptosis through oxidative stress. Clinical experience since the late 1960s has provided initial evidence for a clinical antitumor activity. Our open-label, multicenter phase I clinical trial was designed to further investigate the adverse event (AEs) profile and pharmacokinetics of AOP99.0001 in pretreated myeloma patients and collect initial data on the potential clinical efficacy in this indication. Thirty-six patients with relapsed or refractory myeloma, who had been pretreated with at least two lines of therapy earlier, were included. Imexon was applied intravenously on 5 consecutive days for 2 weeks (d1-5 and d8-12) for a 3-week cycle. The plasma half-life of AOP99.0001 and its active metabolite AOP99.0002 was found to be approximately 1.2 and 2.6 h, respectively. The mean duration of treatment with Imexon was 6.8 weeks in a dose range between 50 and 1000 mg/m without reaching dose-limiting toxicity. Drug-related AEs occurring with a frequency of greater than 10% were fatigue, nausea, constipation, headache, asthenia, anemia, thrombocytopenia, leukopenia and creatinine increase. A total of nine severe adverse events occurred in three patients. No mortality was encountered when patients were on treatment with Imexon. Preliminary antimyeloma efficacy of AOP99.0001 was observed with 1 minimal response, 12 (36%) stable disease responses, and all other evaluable patients had progressive disease. Remarkably, the patient with minimal response also experienced a complete clinical resolution of myeloma-associated polyneuropathy. Overall, Imexon was safe and well tolerated in the dose range investigated. Imexon showed minor clinical activity as a single agent in heavily pretreated myeloma patients. On account of its unique mechanism of action, favorable toxicity profile, initial clinical evidence for antimyeloma activity, and its known synergistic activity in combination with approved agents for myeloma treatment, AOP99.0001 is recommended for future clinical studies in combination regimens in multiple myeloma.
Authors:
Thomas M Moehler; Reinhard Feneberg; Anthony Dick Ho; Anatoly K Golenkov; Heinz Ludwig; Martin Kropff; Nuriet K Khuageva; Jacek Hajda; Ingo von Broen; Hartmut Goldschmidt
Related Documents :
10761055 - Management of myeloma: current and future approaches.
16113665 - Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140...
8507875 - Plasma cell labeling index and beta 2-microglobulin predict survival independent of thy...
8616075 - Plateau phase in multiple myeloma: an analysis of long-term follow-up of 432 patients. ...
7003335 - Implementation of adjuvant therapy for breast cancer in the st. louis metropolitan area...
25474625 - Distribution and volume of extrauterine disease in uterine serous carcinoma: is minimal...
Publication Detail:
Type:  Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study    
Journal Detail:
Title:  Anti-cancer drugs     Volume:  21     ISSN:  1473-5741     ISO Abbreviation:  Anticancer Drugs     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-07-08     Completed Date:  2010-08-04     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9100823     Medline TA:  Anticancer Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  708-15     Citation Subset:  IM    
Affiliation:
Department of Medicine V, University of Heidelberg, Heidelberg, Germany. Thomas.moehler@med.uni-heidelberg.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antineoplastic Agents / adverse effects,  pharmacokinetics,  therapeutic use*
Apoptosis
Dose-Response Relationship, Drug
Female
Hexanones / adverse effects,  pharmacokinetics,  therapeutic use*
Humans
Male
Maximum Tolerated Dose
Middle Aged
Multiple Myeloma / drug therapy*
Oxidative Stress
Recurrence
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Hexanones; 59643-91-3/4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  XPC gene intron 11 C/A polymorphism is a predictive biomarker for the sensitivity to NP chemotherapy...
Next Document:  Using Database Research to Affect the Science and Art of Medicine.